Nektar Therapeutics (NKTR) Ownership
NKTR ownership summary
as of October 18, 2026- Institutions
- 107.1% of shares outstanding
- Insiders
- 0.38% of shares outstanding
- Shares outstanding
- 34.1M
- Float
- 28.3M shares available to trade
- Short interest
- 22.50% 7.0M shares short
- Days to cover
- 5.30 short interest up 21.5% vs prior month
- Institutions 107.07%
- Insiders 0.38%
NKTR top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | FMR Inc | 14.84% | 5.1M | $181.3M | +764,732 (+17.8%) | June 30, 2026 |
| 2 | BlackRock Inc | 8.62% | 2.9M | $105.3M | +2.2M (+324.7%) | June 30, 2026 |
| 3 | Bvf Inc | 7.00% | 2.4M | $85.6M | −168,520 (−6.6%) | June 30, 2026 |
| 4 | Two Seas Capital LP | 5.74% | 2.0M | $70.1M | +1.2M (+162.9%) | March 31, 2026 |
| 5 | Vanguard Capital Management, LLC | 4.38% | 1.5M | $53.6M | +299,794 (+25.0%) | June 30, 2026 |
| 6 | Two Sigma Investments LLC | 3.52% | 1.2M | $43.0M | +271,263 (+29.1%) | June 30, 2026 |
| 7 | Vestal Point Capital LP | 2.93% | 1.0M | $35.8M | +715,000 (+250.9%) | June 30, 2026 |
| 8 | Morgan Stanley - Brokerage Accounts | 2.74% | 937K | $33.5M | +277,173 (+42.0%) | June 30, 2026 |
| 9 | State Street Corp | 2.66% | 910K | $32.5M | +664,952 (+271.7%) | June 30, 2026 |
| 10 | Geode Capital Management, LLC | 2.58% | 881K | $31.5M | +534,511 (+154.1%) | June 30, 2026 |
| 11 | Prosight Management, LP | 2.37% | 810K | $29.0M | +75,000 (+10.2%) | June 30, 2026 |
| 12 | Armistice Capital, LLC | 2.12% | 724K | $25.9M | +146,000 (+25.3%) | June 30, 2026 |
| 13 | Gilder Gagnon Howe & CO LLC | 1.76% | 601K | $21.5M | +329,115 (+121.1%) | June 30, 2026 |
| 14 | Millennium Management LLC | 1.40% | 478K | $17.1M | +73,843 (+18.3%) | June 30, 2026 |
| 15 | BRAIDWELL LP | 1.39% | 474K | $16.9M | +250,916 (+112.7%) | June 30, 2026 |
| 16 | Sofinnova Ventures | 1.38% | 472K | $16.9M | −37,783 (−7.4%) | June 30, 2026 |
| 17 | Woodline Partners LP | 1.38% | 471K | $16.8M | +55,540 (+13.4%) | June 30, 2026 |
| 18 | Orbimed Advisors LLC | 1.36% | 465K | $16.7M | +190,346 (+69.2%) | June 30, 2026 |
| 19 | UBS Group AG | 1.25% | 428K | $15.3M | +108,228 (+33.8%) | June 30, 2026 |
| 20 | Emerald Advisers, LLC | 1.14% | 390K | $14.0M | −4,446 (−1.1%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 17 holders added 8.2M shares and 3 cut 211K.
NKTR top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Growth Company Fund | 5.42% | 1.9M | $66.2M | +18,741 (+1.0%) | August 31, 2026 |
| 2 | Vanguard MStar Total Stk Mkt Idx Invest | 3.16% | 1.1M | $38.6M | −1,443 (−0.1%) | August 31, 2026 |
| 3 | State Street® SPDR® S&P® Biotech ETF | 2.88% | 982K | $35.1M | −18,750 (−1.9%) | September 30, 2026 |
| 4 | iShares Russell 2000 ETF | 2.61% | 893K | $31.9M | −10,304 (−1.1%) | September 30, 2026 |
| 5 | Fidelity Growth Company K6 | 1.47% | 500K | $17.9M | +5,308 (+1.1%) | August 31, 2026 |
| 6 | Fidelity Series Growth Company | 1.24% | 425K | $15.2M | +4,731 (+1.1%) | August 31, 2026 |
| 7 | Fidelity Small Cap Index | 1.10% | 377K | $13.5M | +3,203 (+0.9%) | July 31, 2026 |
| 8 | iShares Russell 2000 Growth ETF | 0.85% | 289K | $10.3M | −366 (−0.1%) | September 30, 2026 |
| 9 | Vanguard Russell 2000 ETF | 0.59% | 200K | $7.2M | +2,239 (+1.1%) | September 30, 2026 |
| 10 | Schwab US Small-Cap ETF™ | 0.53% | 180K | $6.4M | +117 (+0.1%) | September 30, 2026 |
| 11 | PRIMECAP Odyssey Aggressive Growth | 0.51% | 172K | $6.2M | −6,000 (−3.4%) | June 30, 2026 |
| 12 | Fidelity Extended Market Index | 0.48% | 165K | $5.9M | −1,511 (−0.9%) | August 31, 2026 |
| 13 | Biotech Growth Ord | 0.29% | 98K | $3.5M | +31,100 (+46.6%) | June 30, 2026 |
| 14 | Principal SmallCap Growth I Instl | 0.27% | 94K | $3.4M | −209 (−0.2%) | September 30, 2026 |
| 15 | Vanguard Health Care ETF | 0.26% | 90K | $3.2M | +99 (+0.1%) | September 30, 2026 |
| 16 | Schwab Small Cap Index | 0.25% | 84K | $3.0M | +522 (+0.6%) | August 31, 2026 |
| 17 | Emerald Growth A | 0.25% | 84K | $3.0M | −20,775 (−19.8%) | August 31, 2026 |
| 18 | BlackRock Advantage Small Cap Core Instl | 0.24% | 83K | $3.0M | −7,594 (−8.4%) | August 31, 2026 |
| 19 | PRIMECAP Odyssey Growth | 0.20% | 68K | $2.4M | −300 (−0.4%) | June 30, 2026 |
| 20 | Fidelity Total Market Index | 0.19% | 65K | $2.3M | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
NKTR insider transactions
latest 18| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-18 | Jonathan Zalevsky | Sell | $73.00 | 180 | $13,140 |
| 2026-02-18 | Howard W Robin | Sell | $73.00 | 423 | $30,879 |
| 2026-01-20 | Jonathan Zalevsky | Sell | $35.67 | 3,867 | $137,936 |
| 2025-11-25 | Howard W Robin | Sell | $54.28 | 2,207 | $119,796 |
| 2025-11-25 | Jonathan Zalevsky | Sell | $54.28 | 1,157 | $62,802 |
| 2025-11-25 | Mark Andrew Wilson | Sell | $54.28 | 630 | $34,196 |
| 2025-09-09 | Howard W Robin | Sell | $46.69 | 6,666 | $311,236 |
| 2025-09-05 | Howard W Robin | Sell | $38.53 | 6,666 | $256,841 |
| 2025-09-04 | Jonathan Zalevsky | Sell | $33.52 | 1,721 | $57,688 |
| 2025-09-04 | Howard W Robin | Sell | $33.70 | 5,166 | $174,094 |
| 2025-09-02 | Howard W Robin | Sell | $30.16 | 1,500 | $45,240 |
| 2025-09-02 | Jonathan Zalevsky | Sell | $30.10 | 485 | $14,598 |
| 2025-08-19 | Howard W Robin | Sell | $26.59 | 1,573 | $41,826 |
| 2025-08-19 | Jonathan Zalevsky | Sell | $26.59 | 725 | $19,278 |
| 2025-08-19 | Mark Andrew Wilson | Sell | $26.59 | 676 | $17,975 |
| 2025-05-19 | Howard W Robin | Sell | $10.05 | 1,547 | $15,547 |
| 2025-05-19 | Jonathan Zalevsky | Sell | $10.05 | 714 | $7,176 |
| 2025-05-19 | Mark Andrew Wilson | Sell | $10.05 | 666 | $6,693 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
NKTR shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns NKTR
Institutional investors own 107.1% of Nektar Therapeutics's shares and insiders 0.38%. The largest holder is FMR Inc with 14.84% of the shares (5.1M), as of June 30, 2026. Among the top 20 institutions, 17 added shares and 3 reduced their stake in the latest filings. Short interest is 22.50% of the float, or 5.30 days of average trading volume. The share count rose 135.4% since 2014.
Related: NKTR analyst forecast, NKTR key metrics. See the NKTR stock overview for the latest quote and news.
NKTR ownership FAQ
Who owns the most Nektar Therapeutics stock?
The largest shareholders of Nektar Therapeutics are FMR Inc (14.84%), BlackRock Inc (8.62%), Bvf Inc (7.00%), Two Seas Capital LP (5.74%), Vanguard Capital Management, LLC (4.38%).
What percentage of Nektar Therapeutics is owned by institutions?
Institutions hold 107.1% of Nektar Therapeutics's shares outstanding; insiders hold 0.38%.
Which funds own Nektar Therapeutics?
The largest fund holders of Nektar Therapeutics are Fidelity Growth Company Fund (5.42%), Vanguard MStar Total Stk Mkt Idx Invest (3.16%), State Street® SPDR® S&P® Biotech ETF (2.88%), iShares Russell 2000 ETF (2.61%), Fidelity Growth Company K6 (1.47%).
What is Nektar Therapeutics's short interest?
7.0M shares of Nektar Therapeutics were sold short, 22.50% of the float; at the average daily volume it would take 5.30 days to cover.
Are insiders buying or selling Nektar Therapeutics?
Of the latest 18 reported insider transactions in Nektar Therapeutics (since May 19, 2025), 0 were purchases and 18 were sales.
How many shares of Nektar Therapeutics are outstanding?
Nektar Therapeutics has 34.1M shares outstanding, of which 28.3M are in the public float.